The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Open accessAbstract
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic medical centers in Australia, Canada, France, and the United States. Eligible patients were aged 18 years and older and had advanced or metastatic melanoma. Data were pooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and 520 from randomized cohorts [n = 226 ipilimumab naive; n = 294 ipilimumab treated]). Cutoff dates were April 18, 2014, for safety analyses and October 18, 2014, for efficacy analyses. EXPOSURES: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks continued until disease progression, intolerable toxicity, or investigator decision. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate (best overall response of complete response or partial response) in patients with measurable disease at baseline per independent central review. Secondary end points included toxicity, duration of response, progression-free survival, and overall survival. RESULTS: Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%] men), 581 had measurable disease at baseline. An objective response was reported in 194 of 581 patients (33% [95% CI, 30%-37%]) and in 60 of 133 treatment-naive patients (45% [95% CI, 36% to 54%]). Overall, 74% (152/205) of responses were ongoing at the time of data cutoff; 44% (90/205) of patients had response duration for at least 1 year and 79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients. Median overall survival in the total population was 23 months (95% CI, 20-29) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%). Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade 3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment because of a treatment-related AE. Treatment-related serious AEs were reported in 59 patients (9%). There were no drug-related deaths. CONCLUSIONS AND RELEVANCE: Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01295827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [2]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“In melanoma, anti-PD-1 treatment was more effective in patients with smaller tumors (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“For example, patients with smaller tumors or low serum lactate dehydrogenase (LDH) levels at baseline have a better prognosis and are also more likely to respond to anti-PD-1 treatment (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Patients more likely to benefit from checkpoint immunotherapy include those with tumors demonstrating a high density of somatic mutations, elevated PD-L1 expression and/or are enriched with IFNγ transcriptional profiles (8–13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“Anti-PD-1 immunotherapy has shown efficacy in melanoma, but fewer than half of all melanoma patients treated with anti-PD-1 immunotherapy have a prolonged response5.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma. Lancet. 2014;384(9948):1109-1117.
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002). Lancet Oncol. 2015;16(8):908-918.
- Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1188.
- Kluger HM, Sznol M, Callahan MK et al. Survival, response duration and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558,ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1203.
Cited by
Sorted by citations
Items 701–800 of 1,000
Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage
Fukuda, R., Sugawara, S., & Kondo, Y. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3726-19 · Cited by 9
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Choi, S. H., Mani, M., Kim, J., Cho, W. J., Martin, T. F. J., Kim, J. H., Chu, H. S., Jeong, W. J., Won, Y.-W., Lee, B. J., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02027-x · Cited by 8
Endocrine complications of cancer immunotherapy
Król, A., Gawlik, T., & Jarząb, B. (2018) · Endokrynologia Polska · doi:10.5603/ep.a2018.0073 · Cited by 8
Friedlander, P. A. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.74 · Cited by 8
He, C., Guo, Y., Zhou, N., Wang, Z., Liu, T., Xu, X., Wang, F., Zhu, H., Yang, Z., Yang, X., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s461701 · Cited by 7
An insight into the role of innate immune cells in breast tumor microenvironment
Garg, S., Rai, G., Singh, S., Gauba, P., Ali, J., & Dang, S. (2024) · Breast Cancer · doi:10.1007/s12282-024-01645-8 · Cited by 7
Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations
Kado, S., & Komine, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115370 · Cited by 7
Aptamers Targeting Immune Checkpoints for Tumor Immunotherapy
Abdu, A. M. A., Liu, Y., Abduljabbar, R., Man, Y., Chen, Q., & Liu, Z. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080948 · Cited by 7
Jeong, E., Choi, J. H., Lee, M., Lim, J. H., Jung, S., Woo, Y., Kim, J., Ok, J., Kim, L., Jeong, W., et al. (2025) · Advanced Science · doi:10.1002/advs.202515247 · Cited by 7
Xu, Y., Shen, H., Shang, D., & Zhu, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665239 · Cited by 10
An in vivo method for diversifying the functions of therapeutic antibodies
Tian, M., Cheng, H.-L., Kimble, M. T., McGovern, K., Waddicor, P., Chen, Y., Cantor, E., Qiu, M., Tuchel, M.-E., Dao, M. N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025596118 · Cited by 7
Zheng, J., Zhou, X., Fu, Y., & Chen, Q. (2023) · Cancers · doi:10.3390/cancers15041314 · Cited by 7
Zhong, X. Z., Li, L., Yin, J., Chen, Y., Xin, X., Yu, L., Tang, Y., Zhang, J., & Li, J. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00587-2 · Cited by 7
Resistance Management for Cancer: Lessons from Farmers
Seyedi, S., Harris, V. K., Kapsetaki, S. E., Narayanan, S., Saha, D. K., Compton, Z. T., Yousefi, R., May, A., Fakir, E., Boddy, A. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3374 · Cited by 8
Cohen, G. L., Rapoport, B. L., Chan, S. W., Ruff, P., Arance, A. M., Mujika, K., Houghton, B., Brown, M. P., Zielinski, R. M., Muñoz‐Couselo, E., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309778 · Cited by 7
Zheng, A.-W., Jia, D., Xia, L.-M., Jin, G., Wu, H., & Li, T. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.08.047 · Cited by 7
Novedades en inmunología del melanoma
Escandell, I., Martín, J. M., & Jordá, E. (2017) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2017.01.017 · Cited by 7
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
Flynn, M., Young, K., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786228 · Cited by 7
Fluvastatin exerts an antitumor effect in vemurafenib-resistant melanoma cells
Nishiya, M., Yasuhira, S., Shibazaki, M., Oikawa, H., Masuda, T., & Maesawa, C. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000757 · Cited by 7
Yang, L., Xu, Y., Luo, P., Chen, S., Zhu, H., & Wang, C. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194176 · Cited by 7
Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma
Ziogas, D. C., Konstantinou, F., Bouros, S., & Gogas, H. J. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1711737 · Cited by 8
Wang, B., Liu, M., Ran, Z., Li, X., Li, J., & Ou, Y. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00348 · Cited by 7
Self-citationWhat is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?
Standage, H., Hersh, A. R., Caughey, A. B., Taylor, M. H., Vetto, J. T., & Han, D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09137-7 · Cited by 7
Which factors matter the most? Revisiting and dissecting antibody therapeutic doses
Tang, Y., Li, X., & Cao, Y. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.022 · Cited by 9
Self-citationEV PD-L1 Contributes to Immunosuppressive CD8 + T Cells in Peripheral Blood of Pediatric Wilms Tumor
Zhang, X., Liu, Z., Hou, Y., Jiao, H., Ren, J., & Wang, G. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211041264 · Cited by 7
Pietro, F. R. D., Verkhovskaia, S., Mastroeni, S., Carbone, M. L., ABENI, D. D., Rocco, C. Z. D., Samà, N., Zappalà, A., Marchetti, P., Galitiis, F. D., et al. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.09.006 · Cited by 7
Vaginal Malignant Melanoma: Case Report and Review of the Literature
Walz, D., Cautha, S., Gupta, S., Lombino, M., Suhl, M., Bello, J., & Smith, H. (2022) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2022_003427 · Cited by 7
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop”
Colucci, M., D’Alonzo, V., Santangelo, F., Miracco, C., Valente, M., Maio, M., & Giacomo, A. M. D. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s367389 · Cited by 7
The Role of Hedgehog Signaling in the Melanoma Tumor Bone Microenvironment
Shamsoon, K., Hiraki, D., Yoshida, K., Takabatake, K., Takebe, H., Yokozeki, K., Horie, N., Fujita, N., Nasrun, N. E., Okui, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108862 · Cited by 7
Liu, X., Zhou, Q., Xu, Y., Chen, M., Zhao, J., & Wang, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21160 · Cited by 7
Cost-effectiveness of a melanoma screening programme using whole disease modelling
Buja, A., Rivera, M., Girardi, G., Vecchiato, A., Rebba, V. S., Pizzo, E., Chiarion‐Sileni, V., Palozzo, A. C., Montesco, M. C., Zorzi, M., et al. (2019) · Journal of Medical Screening · doi:10.1177/0969141319885998 · Cited by 7
Hall, K. H., Liu, Y., Jiang, C., & Harvey, R. D. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2354 · Cited by 7
Wang, Z., Hu, N., Li, X., Wang, H., Ren, C., Qiao, C., Chen, G., Wang, J., Zhou, L., Wu, J., et al. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.120.000202 · Cited by 7
Self-citationMuggilli, M., Russell, D. K., & Zhou, Z. (2021) · CytoJournal · doi:10.25259/cytojournal_78_2020 · Cited by 7
Huang, R., Lü, X., Sun, X., & Wu, H. (2024) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320241249395 · Cited by 6
Wang, T., Sun, J., Wang, L., Lin, Y., Wu, Z., Jia, Q., Zhang, S., An, J., Ma, X., Wu, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529710 · Cited by 6
Weichenthal, M., Ellebæk, E., Mangana, J., Asher, N., Gavrilova, I., Sekulović, L. K., Ugurel, S., Hausschild, A., Meier, F. E., Leiter, U., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115339 · Cited by 6
Self-citationElder, A. M., Fairchild, H., Kines, K. T., Cozzens, L. M., Becks, A. R., Slansky, J. E., Anderson, S. M., & Lyons, T. R. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115676 · Cited by 2
Verdegaal, E. M. E., Verpoorte, A. L. C., van der Kooij, M. K., de Bruin, L., Visser, M., van der Minne, C. E., Weeda, V., Roozen, I. C. F. M., Jonker, M. A., Westra, I. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4322 · Cited by 6
Zhu, S., Zhang, X., Liu, W., Zhou, Z., Xiong, S., Chen, X., & Peng, C. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03521-5 · Cited by 6
Yan, C. W., Luo, W., Yang, J., Yang, J., Chen, S., Bergdorf, K. N., Hu, Q., Weiss, V. L., Johnson, D. B., Liu, Q., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67315-1 · Cited by 7
Critical aspects to achieve a high-quality melanoma clinic
Dummer, R., Ramelyte, E., Levesque, M. P., Goldinger, S. M., & Braun, R. P. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000357 · Cited by 6
Targeting Immune Checkpoint Pathways in Melanoma: Triumphs and Challenges
Back, P. I., Rascon, K., Islam, M. R., Selby, C., & La-Beck, N. M. (2023) · Future Drug Discovery · doi:10.4155/fdd-2022-0010 · Cited by 6
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma
Versluis, J. M., Hoefsmit, E. P., Shehwana, H., Dimitriadis, P., Sanders, J., Broeks, A., & Blank, C. U. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03581-6 · Cited by 6
Lee, Y. S., Heo, W., Choi, H.-J., Cho, H.-R., Nam, J. H., Ki, Y. G., Lee, H.-R., Son, W.-C., Park, Y.-S., Kang, C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248870 · Cited by 6
Chai, L. F., Hardaway, J. C., Heatherton, K. R., O’Connell, K. P., Lopes, M. C., Rabinowitz, B. A., Ghosh, C. C., Guha, P., Jaroch, D., Cox, B. F., et al. (2021) · Vaccines · doi:10.3390/vaccines9080807 · Cited by 6
Soma, K., Nishida, T., Osugi, N., Morimura, O., Adachi, S., Fujii, Y., Sugimoto, A., Mukai, K., Nakamatsu, D., Matsumoto, K., et al. (2021) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01542-z · Cited by 6
de Wit, R., Powles, T. B., Castellano, D., Necchi, A., Lee, J., van der Heijden, M. S., Matsubara, N., Bamias, A., Fléchon, A., Sternberg, C. N., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15233 · Cited by 6
Sahin, A., Kocyigit, I. D., Aslan, K., Eroğlu, E., Demiray, A., & Eken, A. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01031-2 · Cited by 6
Grad, R. N., Jung, S., Ye, F., Sun, L., Johnson, D. B., & Agarwal, R. (2023) · The Oncologist · doi:10.1093/oncolo/oyad219 · Cited by 6
Castanares‐Zapatero, D., Verleye, L., Devos, C., Thiry, N., Silversmit, G., Damme, N. V., Gendt, C. D., Hulstaert, F., & Neyt, M. (2024) · International Journal of Dermatology · doi:10.1111/ijd.17046 · Cited by 6
Shrateh, O. N., Abugharbieh, Y., Asbeh, Y. A. A., Hour, H., Awad, I., & Bannoura, S. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02943-9 · Cited by 6
Pembrolizumab in the Treatment of Advanced Urothelial Cancer
Lundgren, K. T., Farina, M. S., & Joaquim Bellmunt, B. (2017) · Future Oncology · doi:10.2217/fon-2017-0284 · Cited by 6
Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1
Meyer, M. A., & DeNardo, D. G. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.029 · Cited by 6
Preliminary report of domperidone (R 33182), a new antiemetic compound. A pilot study.
Helmers, J. H. J. H. (1977) · PubMed · Cited by 6
Cimminiello, C., Indini, A., Guardo, L. D., Prisciandaro, M., Randon, G., Tolomio, E., de Braud, F., & Vecchio, M. D. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000539 · Cited by 6
Cowey, C. L., Scherrer, E., Boyd, M., Aguilar, K. M., Beeks, A., & Krepler, C. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000363 · Cited by 6
Lenci, E., Marcantognini, G., Cognigni, V., Lupi, A., Rinaldi, S., Cantini, L., Fiordoliva, I., Carloni, A. L., Rocchi, M., Zuccatosta, L., et al. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00043 · Cited by 6
Cai, L., Du, X., Zhang, C., Yu, S., Liu, L., Zhao, J., Zhao, Y., Zhang, C., Wu, J., Wang, B., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03095-z · Cited by 6
Tang, W., Shao, R., Wang, J., Scherrer, E., Ma, A., & Aguiar‐Ibáñez, R. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.04.007 · Cited by 6
Howell, A. V., Gebregziabher, M., THIERS, B. H., Graboyes, E. M., Paulos, C. M., Wrangle, J. M., Hunt, K. J., & Wallace, K. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.005 · Cited by 7
Koczka, K., Rigo, R., Batuyong, E., Cook, S. B., Asad, M., Vallerand, I. A., Suo, A. E., Wang, E., & Cheng, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5070 · Cited by 6
Russi, A., Damuzzo, V., Chiumente, M., Pigozzo, J., Cesca, M., Chiarion‐Sileni, V., & Palozzo, A. C. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1311444 · Cited by 6
Malesa, A., Nowak, J., Skórka, K., Karp, M., & Giannopoulos, K. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0025 · Cited by 7
Swetter, S. M. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.05.010 · Cited by 6
Monette, A., Aguilar‐Mahecha, A., Altınmakas, E., Angelos, M. G., Assad, N., Batist, G., Bommareddy, P. K., Bonilla, D. L., Borchers, C. H., Church, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3791 · Cited by 7
Ribas, A., Milhem, M. M., Hoimes, C. J., Amin, A., Lao, C., Conry, R. M., Hunt, J. P., Daniels, G. A., Almubarak, M., Shaheen, M. F., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0987 · Cited by 5
Self-citationLadjevardi, C. O., Naeser, Y., Dyrke, U., Papantoniou, D., Bagge, R. O., Elander, N., Ingvar, C., Flygare, P., Nilsson, C., Jakobsson, F., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00487-5 · Cited by 5
Liu, S., Liu, M., Wang, Z., Hu, S., Zhang, K., Lu, C. F., Cheng, X., Shen, M., Bi, J., Zhu, D., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02890-8 · Cited by 8
Fortman, D. D., Avellan, M. G. P., Hurd, D. E., Schwartz, M. B., Dubner, H. M., Hewitt, C., Berton, S., Ernst, S. J., Rose, A. E., Wangd, H. Z. H., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000871 · Cited by 5
Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro
Cosci, I., Toni, L. D., Fiore, P. D., Nisio, A. D., Carraro, S., Radu, C. M., Bertazza, L., D, S. M. M., Pigozzo, J., Crivellaro, G., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1534975 · Cited by 5
Wang, H., Xuan, T., Chen, Y., Yu, H., Gu, T.-T., Zhou, G. Q., Liang, L., & Cao, F. (2020) · Immunotherapy · doi:10.2217/imt-2020-0063 · Cited by 5
Subacute CNS Demyelination After Treatment With Immune Checkpoint Inhibitors
Tan, E., Shaw, H. M., Nathan, P., Ghosh-Ray, S., & Ottaviani, D. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001069 · Cited by 5
Harsten, R., FISHER, R. J., Alsanjari, N., Idaewor, P. E., & Al‐Zawi, A. S. A. (2021) · Cureus · doi:10.7759/cureus.15886 · Cited by 5
Proteomic profiling of cutaneous melanoma explains the aggressiveness of distant organ metastasis
Azimi, A., Patrick, E., Teh, R., Kim, J., & Fernandez‐Penas, P. (2023) · Experimental Dermatology · doi:10.1111/exd.14814 · Cited by 5
Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma
Trilla‐Fuertes, L., Gámez‐Pozo, A., Prado-Vázquez, G., López‐Vacas, R., Soriano, V., Garicano, F., Lecumberri, M. J., de la Borbolla, M. R., Majem, M., Pérez-Ruiz, E., et al. (2023) · Cancers · doi:10.3390/cancers15174407 · Cited by 5
The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review
Sabaghian, A., Shamsabadi, S., Momeni, S., Mohammadikia, M., Mohebbipour, K., Sanami, S., Ahmad, S., Akhtar, N., Sharma, N. R., Kushwah, R. B. S., et al. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2024.15 · Cited by 6
Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma
Fong, K. H. A., Ho, I., & So, T. H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1483117 · Cited by 5
Wall, L. M., & Baldwin-Medsker, A. E. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.e260-e266 · Cited by 5
Mattila, K., RAANTA, P., LAHTELA, V., Pyrhönen, S. O., Koskivuo, I., & Vihinen, P. (2018) · Anticancer Research · doi:10.21873/anticanres.12999 · Cited by 5
BRAF Inhibition: Bridge or Boost to T-cell Therapy?
Goff, S. L., & Rosenberg, S. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0286 · Cited by 5
Nursing Care in Dermatologic Oncology: a Qualitative Study
Sibéoni, J., Marc, M., Lagaude, M., Orri, M., Verneuil, L., & Révah‐Levy, A. (2019) · Journal of Cancer Education · doi:10.1007/s13187-019-01573-8 · Cited by 5
Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors
Mladosievičová, B., Országhová, Z., Jablonická, M., Rečková, M., Chovanec, M., & Mego, M. (2020) · Klinicka onkologie · doi:10.14735/amko2020350 · Cited by 5
Lee, S., Bennett, A. V., Zhou, X., Warner, A. B., Trogdon, J. G., Kent, E. E., & Lund, J. L. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5630 · Cited by 5
Winkler, J. K., Buder‐Bakhaya, K., Dimitrakopoulou‐Strauss, A., Enk, A., & Hassel, J. C. (2017) · Der Radiologe · doi:10.1007/s00117-017-0281-4 · Cited by 5
Early-phase clinical drug development of novel agents: a changing paradigm
Miguel, M. J. D., & Calvo, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz165 · Cited by 5
Liao, X., Zhao, L., Wu, S., Zheng, H., Chen, H., Zhang, H., Wang, Z., & Lin, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.22938 · Cited by 5
Nagasaka, M., Abdallah, N. H., Crosby, M. A., Thummala, N., Patel, D., Wozniak, A. J., Gadgeel, S. M., Abrams, J., & Sukari, A. W. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s219886 · Cited by 5
Clínica, G. D. T. D. S. B. D. O. (2017) · Brazilian Journal of Oncology · doi:10.1055/s-0044-1792178 · Cited by 5
Alshammari, A. H., Mahdi, M. F., Hirotsu, T., Morishita, M., Hatakeyama, H., & di Luccio, E. (2025) · Biomedicines · doi:10.3390/biomedicines13102409 · Cited by 5
Targeting immune checkpoint therapy: The role of manganese in tumor immunotherapy
Lyu, X., Li, B., & Lin, Z. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.10.001 · Cited by 4
Zhang, R., Wang, Y., Wu, Y., Zheng, B., Cao, Q., Chen, Y., Cao, Z., Zhu, Y., Zhou, L., & Zhang, Q. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013317 · Cited by 4
Nardou, K., Nicolas, M., Kuttler, F., Cisarova, K. V., Çelik, E., Quinodoz, M., Riggi, N., Michielin, O. A., Rivolta, C., Turcatti, G., et al. (2022) · Cancers · doi:10.3390/cancers14061575 · Cited by 4
Monnickendam, G. (2024) · Value in Health · doi:10.1016/j.jval.2024.02.008 · Cited by 4
Jiang, W., Cheng, Y., Hou, L., Huang, Y., Wang, S., Zhang, Y., Jiang, T., Yang, F., & Ma, Z. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124422 · Cited by 4
de Freitas, J. T., Thakur, V., LaPorte, K. M., Thakur, V. S., Flores, B., Caicedo, V., Ajaegbu, C. G. E., Ingrasci, G., Lipman, Z. M., Zhang, K., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03214-5 · Cited by 4
Yu, Y., Wang, Y., Lu, J., Cao, X., Feng, Y., Tu, P., & Lu, Y. (2025) · Inflammation · doi:10.1007/s10753-025-02332-2 · Cited by 3
Towards Predictive Biomarkers for Immunotherapy Response in Breast Cancer Patients
Voorwerk, L., Kat, M., & Kok, M. (2018) · Breast Cancer Management · doi:10.2217/bmt-2017-0014 · Cited by 4
Evaluation of Nivolumab for Ototoxic Effects: An Animal Study in Rats
Güler, İ., Kuzucu, İ., Baklacı, D., Kum, R. O., Özhamam, E. U., & Özcan, M. (2020) · The Journal of International Advanced Otology · doi:10.5152/iao.2020.7123 · Cited by 4
Zhu, P.-F., Chen, Y.-W., Wang, M., Deng, Y.-Y., Pan, S. L., Chen, Z.-L., & Yang, L. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001232 · Cited by 5
Metadata
- Authors
- Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B., Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P., & Robert, C.
- Affiliations
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Westmead Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- South Texas Accelerated Research Therapeutics (US)
- The University of Texas MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- Abramson Cancer Center (US)
- The University of Sydney (AU)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Institut Gustave Roussy (FR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Ribas, Antoni
- Hamid, Omid
- Daud, Adil
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Kefford, Richard
- Joshua, Anthony M.
- Patnaik, Amita
- Hwu, Wen-Jen
- Weber, Jeffrey S.
- Hersey, Peter
- Dronca, Roxana
- Joseph, Richard W.
- Zarour, Hassane
- Chmielowski, Bartosz
- Lawrence, Donald P.
- Algazi, Alain
- Rizvi, Naiyer A.
- Mateus, Christine
- Li, Xiaoyun Nicole
- Robert, Caroline
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1600
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2338494814
- Cited by
- 1,069
- References
- 22
- Citations by year
- 2026: 33 · 2025: 66 · 2024: 67 · 2023: 99 · 2022: 63 · 2021: 123 · 2020: 139 · 2019: 139 · 2018: 145 · 2017: 153 · 2016: 39
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, advanced melanoma, metastatic melanoma, anti-PD-1 therapy, anti-PD-1 monoclonal antibody, objective response rate, overall survival, progression-free survival, duration of response, ipilimumab, immune checkpoint inhibitors, treatment-naive patients, treatment-emergent adverse events, immune-related adverse events, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Rate, Treatment Outcome, Disease Progression, Disease-Free Survival, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
